SCOTT ADRIAN C (US)
DUDLEY AIMEE M (US)
CROMIE GARETH (US)
LO RUSSELL (US)
US20170061070A1 | 2017-03-02 | |||
US20060177847A1 | 2006-08-10 |
ACUNA-HIDALGO ET AL.: "Neu-Laxova Syndrome Is a Heterogeneous Metabolic Disorder Caused by Defects in Enzymes of the L-Serine Biosynthesis Pathway", THE AMERICAN JOURNAL OF HUMAN GENETICS, vol. 95, no. 3, 4 September 2014 (2014-09-04), pages 285 - 293, XP055647477, DOI: 10.1016/j.ajhg.2014.07.012
TUCHMAN M, MORIZONO H, RAJAGOPAL B S, PLANTE R J, ALLEWELL N M: "The biochemical and molecular spectrum of ornithine transcarbamylase deficiency", J. INHER. METAB. DIS., vol. 21, no. S 1, 1 June 1998 (1998-06-01), pages 40 - 58, XP055816557
WHAT IS CLAIMED IS: 1. A method of screening a subject for a disease comprising: a) obtaining genomic DNA from the subject; b) identifying a gene of interest from the genomic DNA; c) inserting the gene into a construct, wherein the construct is a linear DNA; d) providing a test cell, wherein the test cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the test cell; e) introducing the construct into the test cell; f) evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease, wherein the gene of interest is a metabolic gene or a gene from Table 2. 2. The method of claim 1, wherein the subject is a fetus, neonate, juvenile or adult. 3. The method of claim 1 or 2, wherein the cell and the control cell are yeast cells. 4. The method of any one of claims 1-3, wherein the amino acid is arginine. 5. The method of any one of claim 1-4, wherein the subject is pregnant. 6. The method of any one of claims 1-5, wherein the gene encodes OTC, ASS1, or ASL. 7. The method of any one of claims 1-6, wherein cell growth is measured by optical density of a liquid culture, a number of pixels of a colony of cells growing on solid media. 8. The method of any one of claims 1-7, wherein the evaluating step comprises measuring cell growth for 0.5, 2, 4, 6, 8, 10, 12, 24, 36, 72, 96 or 120 hours or any number of hours in between a range defined by any two aforementioned values. 9. The method of any one of claims 1-8, wherein cell growth of the test cell is comparable to that of the control cell by automated image analysis, wherein the test cell has an optical density that is at least 90% of the growth value of the control cell. 10. The method of any one of claims 1-8, wherein cell growth of the test cell is slow as compared to the control cell, wherein the cell has an optical density that is 79% or less than the optical density of the control cell. 11. The method of any one of claims 1-10, wherein the gene of interest is further analyzed for a single-nucleotide polymorphism. 12. The method of any one of claims 11, wherein the single-nucleotide polymorphism is identified as being associated with loss of function or decreased function of a protein encoded by the gene of interest. 13. The method of any one of claims 1-12, wherein a t-test is performed between the test cell and control cell to examine significant growth difference, wherein a t-test p- values < 0.0001 indicates a significant growth difference between the test cell and control cell. 14. The method of claim 13, wherein the significant growth difference indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. 15. The method of any one of claims 1-14, wherein the disease is NLS, Urea Cycle Disorders or retinal neuropathy. 16. A method of determining amino acid deficiency in a subject, the method comprising: a) isolating genomic DNA from a subject; b) detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway; c) inserting the gene into a construct; d) introducing the construct into a test cell; e) growing up the cell in a media absent of an amino acid; and f)) analyzing growth of the test cell in a culture, wherein the growth of the test cell is compared to a control cell, wherein the control cell is not deficient in amino acid synthesis wherein the test cell growth is compared to the control cell, wherein cell growth of the test cell is comparable to that of the control cell indicates that the gene encodes a functional enzyme and wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene encodes a non-functional protein or protein with decreased function and indicates The method of claim 1, wherein the subject is a fetus, neonate, juvenile or adult, wherein the gene is a metabolic gene or a gene from Table 2. 17. The method of claim 16, wherein the cell and the control cell are yeast cells. 18. The method of any one of claims 16-17, wherein the amino acid is arginine. 19. The method of any one of claim 16-18, wherein the subject is pregnant. 20. The method of any one of claims 16-19, wherein the gene encodes OTC, ASS1, or ASL. 21. The method of any one of claims 16-20, wherein cell growth is measured by optical density of a liquid culture, a number of pixels of a colony of cells growing on solid media. 22. The method of any one of claims 16-21, wherein the analyzing step comprises measuring cell growth for 0.5, 2, 4, 6, 8, 10, 12, 24, 36, 72, 96 or 120 hours or any number of hours in between a range defined by any two aforementioned values. 23. The method of any one of claims 16-22, wherein cell growth of the test cell is comparable to that of the control cell by automated image analysis, wherein the test cell has an optical density that is at least 90% of the growth value of the control cell. 24. The method of any one of claims 16-23, wherein cell growth of the test cell is slow as compared to the control cell, wherein the cell has an optical density that is 79% or less than the optical density of the control cell. 25. The method of any one of claims 16-24, wherein the gene of interest is further analyzed for a single-nucleotide polymorphism. 26. The method of any one of claims 25, wherein the single-nucleotide polymorphism is identified as being associated with loss of function or decreased function of a protein encoded by the gene of interest. 27. The method of any one of claims 16-26, wherein a t-test is performed between the test cell and control cell to examine significant growth difference, wherein a t-test p- values < 0.0001 indicates a significant growth difference between the test cell and control cell. 28. The method of claim 27, wherein the significant growth difference indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. 29. The method of any one of claims 16-28, wherein the disease is NLS, Urea Cycle Disorders, retinal neuropathy, or an amino acid deficiency in the subject. 30. The method of any one of claims 16-29, wherein the analyzing step further comprises identifying at least one mutation in the gene. 31. A method of determining a carrier of an amino acid deficiency disorder, the method comprising: a) isolating genomic DNA from a subject; b) detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway, wherein the subject has two different alleles of the gene; c) inserting the gene into a construct, wherein the construct is a linear DNA; d) introducing the construct into a test cell; e) growing up the test cell in a media absent of an amino acid; and f) evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein test cell growth is compared to a control cell that has the homologous gene, wherein test cell growth of the cell is comparable to that of the control cell indicates that the gene of interest encodes a functional protein and wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene of interest encodes a non- functional protein or protein with decreased function and indicates that the subject is a carrier of an amino acid deficiency disorder, wherein the gene is a metabolic gene or a gene from Table 2. 32. The method of claim 31, wherein the amino acid deficiency disorder is NLS. 33. A method of treating a subject with an amino acid deficiency, the method comprising: a) determining a subject or carrier of an amino acid deficiency disorder, wherein the determining comprises: detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway; inserting the gene into a construct, wherein the construct is a linear DNA; introducing the construct into a test cell; growing up the test cell in a media absent of an amino acid; and evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein test cell growth is compared to a control cell that has the homologous gene, wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates that the subject is a carrier of an amino acid deficiency disorder; b) providing an adequate amount of an amino acid supplement to the subject, wherein the gene is a metabolic gene or a gene from Table 2. 34. The method of claim 33, wherein the amino acid supplement is arginine. 35. The method of claim 33 or 34, wherein the enzyme is wherein the gene encodes OTC, ASS1, or ASL. 36. The method of any one of claims 33-35, wherein the subject is a fetus and wherein the mother of the fetus is provided an adequate amount of amino acid supplement. 37. The method of any one of claims 33-36, wherein the evaluating further comprises comparing growth of the test cell to a second control cell, wherein the second control cell is deficient in arginine biosynthesis. 38. The method of any one of claims 33-37, wherein the amino acid deficiency disorder is NLS. 39. A method of prenatal prediction of an amino acid deficiency, the method comprising a) obtaining genomic DNA from a female and male subject; b) identifying a same gene of interest from the genomic DNA of the female and male subject, wherein the subjects are homozygous or heterozygous for the gene; c) inserting a first gene variant of interest from the female into a first construct, wherein the first construct is a linear DNA; d) inserting a second gene variant of interest from the male into a second construct, wherein the second construct is a linear DNA; e) providing a first cell, wherein the first cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell; f) providing a second cell, wherein the second cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell; g) introducing the first construct into the first cell, wherein the first construct is a linear DNA; h) introducing the second construct into the second cell, wherein the second construct is a linear DNA; and i) evaluating the first and second cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the first and second cell are compared to a control cell that has the homologous gene, wherein cell growth of the first and/or second cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the first and second cell is slow as compared to the control cell indicates that the first and second gene of interest encodes a non-functional protein or protein with decreased function and indicates that the male and/or female is a carrier of a disease for an amino acid deficiency, wherein the same gene of interest is a metabolic gene or a gene from Table 2. 40. The method of claim 39, wherein the method further comprises making a diploid strain of a third cell, wherein the third cell comprises the first and second gene of interest and evaluating the third cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the third cell are compared to a control cell that has the homologous gene, wherein cell growth of the third cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the third cell is slow as compared to the control cell indicates that the first and second gene of interest together indicates a predicted fetus with an amino acid deficiency. 41. The method of any one of claims 39-40, wherein data from the first, second and third cell is stored in a look-up table, wherein the look-up table is generated for disease prediction. 42. The method of any one of claims 39-41, wherein the disease for an amino acid deficiency is NLS. 43. A method of prenatal prediction of an amino acid deficiency wherein at least one parent has a gene mutation, the method comprising: a) obtaining genomic DNA from a female and male subject; b) identifying a same gene of interest from the genomic DNA of the female and male subject, wherein the subjects are homozygous or heterozygous for the gene; c) inserting a first gene of interest from the female into a first construct; d) inserting a second gene of interest from the male into a second construct; e) providing a first cell, wherein the first cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell; f) providing a second cell, wherein the second cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell; g) making a diploid strain of a third cell, wherein the third cell comprises the first and second gene of interest h) introducing the first construct into the first cell, wherein the first construct is a linear DNA; i) introducing the second construct into the second cell, wherein the second construct is a linear DNA; and j) evaluating the first, second, and third cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the first and second cell are compared to a control cell that has the homologous gene, wherein cell growth of the first, second and third cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the first, second and third cell is slow as compared to the control cell indicates that the first and second gene of interest encodes a non-functional protein or protein with decreased function and predicts an amino acid deficiency for progeny, wherein the same gene of interest is a metabolic gene or a gene from Table 2. 44. The method of claim 43, wherein the first gene of interest or the second gene of interest comprises the gene mutation. 45. The method of claim 43 or 44, wherein the gene of interest encodes OTC, ASS1, or ASL. 46. The method of any one of claims 43-45, wherein the gene of interest encodes OTC, ASS1, or ASL with at least one of the amino mutations otc-R141Q, ass1-R127W, asl- Q286R . 47. The method of any one of claims 43-46, wherein data from the first, second and third cell is stored in a look-up table, wherein the look-up table is generated for disease prediction. 48. The method of any one of claims 43-47, wherein the amino acid deficiency is caused by NLS. 49. A kit for determining amino acid deficiency comprising: a look-up table, wherein the look up table indicates genes or combinations of genes that may be indicative of an amino acid deficiency or disease; one or more nucleic acid probes for detecting one or more mutation in OTC, ASS1, or ASL, wherein the one or more mutation includes at least: otc-R141Q, ass1-R127W, asl-Q286R. 50. A method of determining if a subject is suffering from an amino acid deficiency, the method comprising: providing a look-up table, wherein the look-up table comprises genes or a combination of genes that are indicative of a disease; isolating genes of interest from a subject; determining if the genes include one of more mutations in the look-up table; and determining a probability of disease in the subject, wherein the genes or a combination of genes are metabolic genes or genes from Table 2. 51. The method of claim 51, wherein the look up table comprises combination of genes that include genes of OTC, ASS1, or ASL, wherein the OTC, ASS1, or ASL genes encode OTC, ASS1, or ASL comprising mutations otc-R141Q, ass1-R127W, asl-Q286R. 52. The method of claim 52, wherein the look up table comprises a list of mutations that have been determined by the method of claim 43, said method further comprising administering an amino acid supplement to the subject to treat the amino acid deficiency if the subject has more than a 50% probability of having the amino acid deficiency. 53. The method of claim 54, wherein the at least one mutation is otc-R141Q, ass1-R127W, asl-Q286R, and wherein the subject is an unborn child of a mother, wherein the mother is tested for the presence of the at least one mutation. 54. A method of identifying a point mutation as a cause or marker of an amino acid deficiency, the method comprising: a) obtaining genomic DNA from a subject having the amino acid deficiency; b) identifying a point mutation in the genomic DNA in at least one of OTC, ASS1, or ASL; c) providing a test yeast cell, wherein a homologous gene of at least one of OTC, ASS1, or ASL has been knocked out of the test yeast cell; d) introducing the gene with the point mutation into the test yeast cell; and e) evaluating the test yeast cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test yeast cell growth is compared to a control cell that has the homologous gene, wherein when test yeast cell growth is comparable to that of the control cell it indicates that the point mutation still allows for a functional protein, and wherein when the test yeast cell growth is slow as compared to the control cell it indicates that the point mutation results in a non-functional protein or protein with decreased function, thereby identifying the point mutation as a cause or marker of an amino acid deficiency. 55. A method of preparing a personalized yeast model for determining a subject at risk of a disease, the method comprising a) obtaining genomic DNA from the subject; b) identifying a gene of interest in at least two alleles from the genomic DNA; c) inserting the gene into a construct, wherein the construct is a linear DNA; d) providing a test cell, wherein the test cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the test cell; e) introducing the construct into the test cell; f) evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease; g) generating data for a look-up table; and h) generating one or more personalized disease amelioration recommendations for the subject; and presenting the one or more personalized disease prevention recommendations for the subject in the personalized disease prevention plan for the subject for disease management, wherein the gene of interest is a metabolic gene or a gene from Table 2. 56. The method of claim 55, wherein the method further comprising: a) obtaining a second genomic DNA from a second subject, wherein the second subject has a second set of two alleles that are related to the two alleles of the subject, and second set of two alleles have a second gene of interest, wherein the second gene of interest is placed in a second construct b) introducing the second construct into a second test cell, evaluating the second test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when second test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function. 57. The method of claim 56, further comprising obtaining a second genomic DNA from a second subject and identifying a second gene(s) of interest in at least two alleles from the genomic DNA, inserting at least one of the second gene(s) into a second construct, introducing the second construct into a second test cell, and mating the second cell with the first cell to produce a progeny cell. 58. The method of claim 57, further comprising evaluating the progeny cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when progeny cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the progeny cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. 59. The method of any of claims 1-15, wherein the evaluating further comprises quantifying cell growth by photographing yeast growing on solid agar plates and performing image analysis using a custom software. 60. The method or kit of any of the preceding claims, wherein the codons in the gene are reverse harmonized. 61. The method or kit of claim 60, wherein the codons in the gene are reverse harmonized for expression in yeast 62. The method or kit of claim 60, wherein the gene is codon optimized for expression in yeast based on a frequency of usage of a codon in yeast. 63. The method or kit of any of the preceding claims, wherein the disease is a urea cycle disorder. 64. The method or kit of any of the preceding claims, wherein the disease is a urea cycle disorder caused by a mutation in one or more of OCT, ASS1, or ASL. 65. A method of codon optimization by reverse harmonization, the method comprising: obtaining a sequence of a first gene/cDNA to be optimized from a first organism; obtaining a sequence of a second gene/cDNA from a second organism, wherein the second gene/cDNA is an ortholog of the first gene/cDNA, and the first gene/cDNA is to be optimized for expression in the second organism; performing a first alignment of the first and second gene/cDNA sequences; obtaining a protein sequence encoded by the a first gene/cDNA; obtaining a protein sequence encoded by the second gene/cDNA; performing a second alignment of the protein sequences encoded by the firs tan d second gene/cDNA; identifying positions in the first alignment where codons that mutually correspond to each other in the first and second gene/cDNA sequences encode the same amino acid at mutually corresponding positions in the second alignment; and replacing the codon in the first gene/cDNA with the codon in the second gene/cDNA, if the codons in the first and second gene/cDNA that encode the same amino acid at mutually corresponding positions in the second alignment are different between the first and second gene/cDNA, thereby obtaining a codon optimized first gene/cDNA from the first organism. 66. The method of claim 65, further comprising: identifying positions in the first alignment where codons differ between the first and the second genes/DNA; and replacing codons in the first gene/cDNA lacking corresponding codons in the second gene/cDNA by selecting codons from the second organism that encode the same amino acid. 67. The method of claim 66, wherein selecting codons from the second organism is based on a frequency of usage of a codon encoding a particular amino acid in the second organism. 68. The method of claims 65-67, wherein a protein encoded by the codon optimized first gene/cDNA is expressed more efficiently and at a higher level in the second organism as compared to a codon non-optimized first gene/cDNA. 69. The method of claims 65-68, wherein the protein encoded by the codon optimized first gene/cDNA is a protein expressed more efficiently and at a higher level in the second organism for an application selected from the group consisting of beer production, wine production, baking, bioremediation, oil remediation, industrial ethanol production, production of nutritional supplements, production of probiotics, protein expression for biochemical and/or biophysical research, and protein therapy. |
[0139] In some embodiments, custom software used in performing image analysis include, without limitations, ImageJ/FIJI, Cell Profiler/Cell Analyst, Neuronstudio, Volume Integration and Alignment System (VIAS), and L-measure. [0140] In some embodiments, a method of determining an amino acid deficiency in a subject comprises: [0141] a) isolating genomic DNA from a subject; [0142] b) detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway; [0143] c) inserting the gene into a construct; [0144] d) introducing the construct into a test cell; [0145] e) growing up the cell in a media absent of an amino acid; and [0146] f) analyzing growth of the test cell in a culture, wherein the growth of the test cell is compared to a control cell, wherein the control cell is not deficient in amino acid synthesis wherein the test cell growth is compared to the control cell, wherein cell growth of the test cell is comparable to that of the control cell indicates that the gene encodes a functional enzyme and wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene encodes a non-functional protein or protein with decreased function and indicates [0147] In some embodiments of the method of determining amino acid deficiency, the subject is a fetus, neonate, juvenile or adult, wherein the gene is a metabolic gene or a gene from Table 2. [0148] In some embodiments of the method of determining amino acid deficiency, the cell and the control cell are yeast cells. [0149] In some embodiments of the method of determining amino acid deficiency, the amino acid is arginine. [0150] In some embodiments of the method of determining amino acid deficiency, the subject is pregnant. [0151] In some embodiments of the method of determining amino acid deficiency, the gene encodes OTC, ASS1, or ASL. [0152] In some embodiments of the method of determining amino acid deficiency, cell growth is measured by optical density of a liquid culture, a number of pixels of a colony of cells growing on solid media. [0153] In some embodiments of the method of determining amino acid deficiency, the analyzing step comprises measuring cell growth for 0.5, 2, 4, 6, 8, 10, 12, 24, 36, 72, 96 or 120 hours or any number of hours in between a range defined by any two aforementioned values. [0154] In some embodiments of the method of determining amino acid deficiency, cell growth of the test cell is comparable to that of the control cell by automated image analysis, wherein the test cell has an optical density that is at least 90% of the growth value of the control cell. [0155] In some embodiments of the method of determining amino acid deficiency, cell growth of the test cell is slow as compared to the control cell, wherein the cell has an optical density that is 79% or less than the optical density of the control cell. [0156] In some embodiments of the method of determining amino acid deficiency, the gene of interest is further analyzed for a single-nucleotide polymorphism. [0157] In some embodiments of the method of determining an amino acid deficiency, the single-nucleotide polymorphism is identified as being associated with loss of function or decreased function of a protein encoded by the gene of interest. [0158] In some embodiments of the method of determining amino acid deficiency, a t-test is performed between the test cell and control cell to examine significant growth difference, wherein a t-test p-values < 0.0001 indicates a significant growth difference between the test cell and control cell. [0159] In some embodiments of the method of determining amino acid deficiency, the significant growth difference indicates that the gene of interest encodes a non- functional protein or protein with decreased function and indicates the disease. [0160] In some embodiments of the method of determining amino acid deficiency, the disease is NLS, Urea Cycle Disorders, retinal neuropathy, or an amino acid deficiency in the subject. [0161] In some embodiments of the method of determining amino acid deficiency, the analyzing step further comprises identifying at least one mutation in the gene. [0162] In some embodiments, a method of determining a carrier of an amino acid deficiency disorder comprises: isolating genomic DNA from a subject; detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway, wherein the subject has two different alleles of the gene; inserting the gene into a construct, wherein the construct is a linear DNA; introducing the construct into a test cell; growing up the test cell in a media absent of an amino acid; and evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein test cell growth is compared to a control cell that has the homologous gene, wherein test cell growth of the cell is comparable to that of the control cell indicates that the gene of interest encodes a functional protein and wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates that the subject is a carrier of an amino acid deficiency disorder, wherein the gene is a metabolic gene or a gene from Table 2. [0163] In some embodiments, of the method of determining a carrier, the amino acid deficiency disorder is NLS. [0164] In some embodiments, a method of treating a subject with an amino acid deficiency comprises: determining a subject or carrier of an amino acid deficiency disorder, wherein the determining comprises: detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway; inserting the gene into a construct, wherein the construct is a linear DNA; introducing the construct into a test cell; growing up the test cell in a media absent of an amino acid; and evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein test cell growth is compared to a control cell that has the homologous gene, wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene of interest encodes a non- functional protein or protein with decreased function and indicates that the subject is a carrier of an amino acid deficiency disorder; providing an adequate amount of an amino acid supplement to the subject, wherein the gene is a metabolic gene or a gene from Table 2. [0165] In some embodiments of the method of treating a subject, the amino acid supplement is arginine. [0166] In some embodiments of the method of treating a subject, the enzyme is wherein the gene encodes OTC, ASS1, or ASL. [0167] In some embodiments of the method of treating a subject, the subject is a fetus and wherein the mother of the fetus is provided an adequate amount of amino acid supplement. [0168] In some embodiments of the method of treating a subject, evaluating further comprises comparing growth of the test cell to a second control cell, wherein the second control cell is deficient in arginine biosynthesis. [0169] In some embodiments of the method of treating a subject, the amino acid deficiency disorder is NLS. [0170] In some embodiments, a method of prenatal prediction of an amino acid deficiency comprises: obtaining genomic DNA from a female and male subject; identifying a same gene of interest from the genomic DNA of the female and male subject, wherein the subjects are homozygous or heterozygous for the gene; inserting a first gene variant of interest from the female into a first construct, wherein the first construct is a linear DNA; inserting a second gene variant of interest from the male into a second construct, wherein the second construct is a linear DNA; providing a first cell, wherein the first cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell; providing a second cell, wherein the second cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell; introducing the first construct into the first cell, wherein the first construct is a linear DNA; introducing the second construct into the second cell, wherein the second construct is a linear DNA; and evaluating the first and second cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the first and second cell are compared to a control cell that has the homologous gene, wherein cell growth of the first and/or second cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the first and second cell is slow as compared to the control cell indicates that the first and second gene of interest encodes a non-functional protein or protein with decreased function and indicates that the male and/or female is a carrier of a disease for an amino acid deficiency, wherein the same gene of interest is a metabolic gene or a gene from Table 2. [0171] In some embodiments, the method of prenatal prediction of an amino acid deficiency further comprises making a diploid strain of a third cell, wherein the third cell comprises the first and second gene of interest and evaluating the third cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the third cell are compared to a control cell that has the homologous gene, wherein cell growth of the third cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the third cell is slow as compared to the control cell indicates that the first and second gene of interest together indicates a predicted fetus with an amino acid deficiency. [0172] In some embodiments of the method of prenatal prediction of an amino acid deficiency, data from the first, second and third cell is stored in a look-up table, wherein the look-up table is generated for disease prediction. [0173] In some embodiments of the method of prenatal prediction of an amino acid deficiency, the disease for an amino acid deficiency is NLS. [0174] In some embodiments, a method of prenatal prediction of an amino acid deficiency wherein at least one parent has a gene mutation comprises: a) obtaining genomic DNA from a female and male subject; b) identifying a same gene of interest from the genomic DNA of the female and male subject, wherein the subjects are homozygous or heterozygous for the gene; c) inserting a first gene of interest from the female into a first construct; d) inserting a second gene of interest from the male into a second construct; e) providing a first cell, wherein the first cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell; f) providing a second cell, wherein the second cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell; g) making a diploid strain of a third cell, wherein the third cell comprises the first and second gene of interest; h) introducing the first construct into the first cell, wherein the first construct is a linear DNA; i) introducing the second construct into the second cell, wherein the second construct is a linear DNA; and j) evaluating the first, second, and third cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the first and second cell are compared to a control cell that has the homologous gene, wherein cell growth of the first, second and third cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the first, second and third cell is slow as compared to the control cell indicates that the first and second gene of interest encodes a non-functional protein or protein with decreased function and predicts an amino acid deficiency for progeny, wherein the same gene of interest is a metabolic gene or a gene from Table 2. [0175] In some embodiments of the method of prenatal prediction of an amino acid deficiency wherein at least one parent has a gene mutation, the first gene of interest or the second gene of interest comprises the gene mutation. [0176] In some embodiments of the method of prenatal prediction of an amino acid deficiency wherein at least one parent has a gene mutation, the gene of interest encodes OTC, ASS1, or ASL. [0177] In some embodiments of the method of prenatal prediction of an amino acid deficiency wherein at least one parent has a gene mutation, the gene of interest encodes OTC, ASS1, or ASLwith at least one of the amino mutations otc-R141Q, ass1-R127W, asl- Q286R . [0178] In some embodiments of the method of prenatal prediction of an amino acid deficiency wherein at least one parent has a gene mutation, data from the first, second and third cell is stored in a look-up table, wherein the look-up table is generated for disease prediction. [0179] In some embodiments of the method of prenatal prediction of an amino acid deficiency wherein at least one parent has a gene mutation, the amino acid deficiency is caused by NLS. [0180] In some embodiments, a kit for determining amino acid deficiency comprises: a look-up table, wherein the look up table indicates genes or combinations of genes that may be indicative of an amino acid deficiency or disease; one or more nucleic acid probes for detecting one or more mutation in OTC, ASS1, or ASL, wherein the one or more mutation includes at least: otc-R141Q, ass1-R127W, asl-Q286R. [0181] In some embodiments, the kit further comprising a arginine supplement in an amount sufficient to treat a subject suffering from arginine deficiency (e.g., Urea Cycle Disorders). [0182] In some embodiments, a method of determining if a subject is suffering from an amino acid deficiency comprises: providing a look-up table, wherein the look-up table comprises genes or a combination of genes that are indicative of a disease; isolating genes of interest from a subject; determining if the genes include one of more mutations in the look-up table; and determining a probability of disease in the subject, wherein the genes or a combination of genes are metabolic genes or genes from Table 2. [0183] In some embodiments of the method of determining if a subject is suffering from an amino acid deficiency, the look up table comprises combination of genes that include genes of OTC, ASS1, or ASL, wherein the OTC, ASS1, or ASL genes encode OTC, ASS1, or ASL comprising mutations otc-R141Q, ass1-R127W, asl-Q286R. [0184] In some embodiments of the method of determining if a subject is suffering from an amino acid deficiency, the look up table comprises a list of mutations that have been determined by the method of claim 43, said method further comprising administering an amino acid supplement to the subject to treat the amino acid deficiency if the subject has more than a 50% probability of having the amino acid deficiency. [0185] In some embodiments, a method of treating a subject with an amino acid deficiency comprises: a) determining if a subject has at least one mutation in OTC, ASS1, or ASL located at otc-R141Q, ass1-R127W, asl-Q286R; and b) providing an adequate amount of a arginine supplement to the subject if the subject has the at least one mutation. [0186] In some embodiments of the method of treating a subject with an amino acid deficiency, the at least one mutation is otc-R141Q, ass1-R127W, asl-Q286R, and wherein the subject is an unborn child of a mother, wherein the mother is tested for the presence of the at least one mutation. [0187] In some embodiments, a method of identifying a point mutation as a cause or marker of an amino acid deficiency comprises: obtaining genomic DNA from a subject having the amino acid deficiency; identifying a point mutation in the genomic DNA in at least one of OTC, ASS1, or ASL; providing a test yeast cell, wherein a homologous gene of at least one of OTC, ASS1, or ASL has been knocked out of the test yeast cell; introducing the gene with the point mutation into the test yeast cell; and evaluating the test yeast cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test yeast cell growth is compared to a control cell that has the homologous gene, wherein when test yeast cell growth is comparable to that of the control cell it indicates that the point mutation still allows for a functional protein, and wherein when the test yeast cell growth is slow as compared to the control cell it indicates that the point mutation results in a non-functional protein or protein with decreased function, thereby identifying the point mutation as a cause or marker of an amino acid deficiency. [0188] In some embodiments, a method of preparing a personalized yeast model for determining a subject at risk of a disease comprises: a) obtaining genomic DNA from the subject; b) identifying a gene of interest in at least two alleles from the genomic DNA; c) inserting the gene into a construct, wherein the construct is a linear DNA; d) providing a test cell, wherein the test cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the test cell; e) introducing the construct into the test cell; f) evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease; g) generating data for a look-up table; and h) generating one or more personalized disease amelioration recommendations for the subject; and presenting the one or more personalized disease prevention recommendations for the subject in the personalized disease prevention plan for the subject for disease management, wherein the gene of interest is a metabolic gene or a gene from Table 2. [0189] In some embodiments of the method of preparing a personalized yeast model, the method further comprising: a) obtaining a second genomic DNA from a second subject, wherein the second subject has a second set of two alleles that are related to the two alleles of the subject, and second set of two alleles have a second gene of interest, wherein the second gene of interest is placed in a second construct b) introducing the second construct into a second test cell, evaluating the second test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when second test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function. [0190] In some embodiments, the method of preparing a personalized yeast model further comprising obtaining a second genomic DNA from a second subject and identifying a second gene(s) of interest in at least two alleles from the genomic DNA, inserting at least one of the second gene(s) into a second construct, introducing the second construct into a second test cell, and mating the second cell with the first cell to produce a progeny cell. [0191] In some embodiments, the method of preparing a personalized yeast model further comprising evaluating the progeny cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when progeny cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the progeny cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. [0192] In some embodiments, any and/or all of the methods provided herein can employ the following codon optimization. Reverse harmonization [0193] Some embodiments herein relate to methods for codon harmonization in which the codons of a heterologous protein coding sequence are altered to more closely match the usage frequency of the codons in orthologous positions of the host organism’s orthologous gene, even if the amino acids encoded at those position differ between the two orthologs. [0194] Some embodiments herein relate to methods of selecting codons for optimization of a sequence involving a process that is the opposite/reverse of the normal harmonization method (“reverse harmonization”). [0195] Without being limited by any particular theory, most heterologous expression strategies are focused on the goal of expressing as much of the protein as possible. Thus, these strategies often use really strong promoters to express high levels of mRNA and codon optimization that replaces rare codons with more frequently used ones. In some embodiments, an innovative aspect of the methods of codon optimization herein is to not try and make the most possible as fast as possible. Without being limited by any particular theory, it is believed that the host (e.g., yeast) regulatory sequences (transcriptional promoters, transcriptional terminators, RNA stability elements, and rates of translation, i.e., codon usage) have evolved to make the optimal amount of a given protein/enzyme under a given environmental condition. Furthermore, without being limited by any particular theory, it is believed that if the optimal amount of a given protein/enzyme that the host needs is made, the assay for the function of that protein/enzyme (e.g., yeast growth) will work better. Thus, these aspects can be applied in one or more of the reverse harmonization methods provided herein. [0196] In some embodiments, reverse harmonization involves selecting one or more cDNAs from a first organism to be codon optimized with respect to its ortholog from a second organism. In some embodiments, the cDNA from the first organism to be codon optimized is aligned (for example, using a alignment tool such as Clustal Omega) to its ortholog from the second organism. The protein sequence encoded by the cDNA from the first organism to be codon optimized is also aligned with the protein sequence encoded by its ortholog from the second organism. [0197] In some embodiments, a method of codon optimization by reverse harmonization comprises obtaining a sequence of a first gene/cDNA to be optimized from a first organism; obtaining a sequence of a second gene/cDNA from a second organism, wherein the second gene/cDNA is an ortholog of the first gene/cDNA, and the first gene/cDNA is to be optimized for expression in the second organism; performing a first alignment of the first and second gene/cDNA sequences; obtaining a protein sequence encoded by the a first gene/cDNA; obtaining a protein sequence encoded by the second gene/cDNA; performing a second alignment of the protein sequences encoded by the firs tan d second gene/cDNA; identifying positions in the first alignment where codons that mutually correspond to each other in the first and second gene/cDNA sequences encode the same amino acid at mutually corresponding positions in the second alignment; and replacing the codon in the first gene/cDNA with the codon in the second gene/cDNA, if the codons in the first and second gene/cDNA that encode the same amino acid at mutually corresponding positions in the second alignment are different between the first and second gene/cDNA, thereby obtaining a codon optimized first gene/cDNA from the first organism. [0198] In some embodiments, the method of codon optimization by reverse harmonization further comprises identifying positions in the first alignment where codons differ between the first and the second genes/DNA; and replacing codons in the first gene/cDNA lacking corresponding codons in the second gene/cDNA by selecting codons from the second organism that encode the same amino acid. [0199] In some embodiments of the method of codon optimization by reverse harmonization, selecting codons from the second organism is based on a frequency of usage of a codon encoding a particular amino acid in the second organism. [0200] In some embodiments of the method of codon optimization by reverse harmonization, the frequency of usage of a codon encoding a particular amino acid in the second organism is the same or approximately the same as the frequency of usage of a codon encoding a particular amino acid in the first organism. For example, the frequency of usage of a codon encoding a particular amino acid is 10% in both the first and second organisms. In some embodiments, when the frequency of usage of a codon encoding a particular amino acid is approximately same between the first and second organism, the frequency of usage of a codon encoding a particular amino acid can vary by about ±10% between the two organisms (Tables 0.4 and 0.5). In some embodiments, the frequency of usage of a codon encoding a particular amino acid can vary by about ±20% between the two organisms (Tables 0.4 and 0.5). In some embodiments, the frequency of usage of a codon encoding a particular amino acid can vary by about ±30% between the two organisms (Tables 0.4 and 0.5). In some embodiments, the frequency of usage of a codon encoding a particular amino acid can vary by about ±40% between the two organisms (Tables 0.4 and 0.5). In some embodiments, the frequency of usage of a codon encoding a particular amino acid can vary by about ±50% between the two organisms (Tables 0.4 and 0.5). In some embodiments, the frequency of usage of a codon encoding a particular amino acid can vary by about ±60% between the two organisms (Tables 0.4 and 0.5). [0201] n some embodiments of the method of codon optimization by reverse harmonization, the frequency of usage of a codon encoding a particular amino acid in the second organism is different than the frequency of usage of a codon encoding a particular amino acid in the first organism. For example, the frequency of usage of a codon encoding a particular amino acid is 10% in the first organism, and the frequency of usage of a codon encoding the same amino acid is 30% in the second organism. [0202] In some embodiments of the method of codon optimization by reverse harmonization, a protein encoded by the codon optimized first gene/cDNA is expressed more efficiently and/or at a higher level in the second organism as compared to a codon non- optimized first gene/cDNA. In some embodiments, the protein is expressed at higher levels. [0203] For example, in some embodiments, reverse harmonization involves selecting one or more human cDNAs to be codon optimized with respect to its yeast ortholog. In some embodiments, the human cDNA to be codon optimized is aligned with its yeast ortholog. The protein sequence encoded by the human cDNA to be codon optimized is also aligned with the protein sequence encoded by its yeast ortholog. For positions that encode the same amino acids in the alignment, if the human codons encoding those amino acids are different from the corresponding yeast codons for those amino acids, the human codons encoding those amino acids are replaced with the corresponding yeast codons for those amino acids. Thereafter, for the remaining amino acid positions that align between the two sequences, the frequency of usage of the codon/codons for a particular amino acid in the human sequence is compared to the frequency of usage of the same codon in yeast. For any codon comparisons where the codons are different and the frequency of occurrence of the codons are different between the organisms, one will alter the codon used in the foreign gene so that it has the same frequency of occurrence as the gene in the host organism. Thus, if a first amino acid in the host gene is different from a first amino acid in the foreign gene, one determines the frequency of occurrence of the codon in the host gene (e.g., 20%) and then selects a codon for the foreign gene that still encodes for the first amino acid of the foreign gene, but has a frequency of occurrence in the host that is closest to 20%. The goal of this optimization is to achieve a rate of translation of the foreign protein that is close to that of the orthologous ”native” protein in the host. [0204] In some embodiments, the protein encoded by the codon optimized first gene/cDNA is a protein expressed more efficiently and at a higher level in the second organism for an application selected from the group consisting of, without limitations, beer production, wine production, baking, bioremediation, oil remediation, industrial ethanol production, production of nutritional supplements, production of probiotics, protein expression for biochemical and/or biophysical research, and protein therapy. In some embodiments of the method of codon optimization by reverse harmonization, the protein encoded by the codon optimized first gene/cDNA is a protein expressed more efficiently and at a higher level in the second organism for an application selected from the group consisting of biofuel production, antibody screening, and/or antibody production. [0205] In some embodiments of the method of codon optimization by reverse harmonization, about 1% to about 50% of the first gene/cDNA is codon optimized. In some embodiments, about 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55% of the first gene/cDNA is codon optimized. In some embodiments, more than about 50% of the first gene/cDNA is codon optimized. [0206] In some embodiments, positions where both human and yeast cDNAs encode the same amino acid can be identified. [0207] In some embodiments, codons in the human cDNA can be replaced with the yeast codon used at that position in the alignment, if the human and yeast codons are different, and if the amino acid at that position is identical between the two organisms. [0208] In some embodiments, for the remaining amino acids positions that align between the two sequences (e.g. not in gaps), it can be checked whether the frequency of codon in humans is comparable to the frequency of that codon in yeast. [0209] Some embodiments herein relate to methods of reverse harmonization of codons. Some embodiments herein relate to methods of reverse harmonization of codon of human genes. Some embodiments herein relate to methods of reverse harmonization of codon of human genes for expressing in yeast. [0210] In some embodiments, the methods of codon harmonization outperform the native human gene/cDNA and/or some other publicly available codon optimization algorithms. [0211] Figure 20 show an embodiment of a codon harmonization method described herein. In some embodiments, human cDNA and yeast cDNA sequences (both products of nature) for two orthologous genes are aligned (Figures 20-28). In some embodiments, any of these genes or gene pairs can be used in any one or more of the embodiments provided herein. Figures 21, 23, 25, and 27 also include the recoded sequence in line with the reverse harmonization aspects provided herein. [0212] Figure 29 shows an embodiment of a codon optimized ASL protein coding nucleotide sequence (SEQ ID NO: 24) generated after the harmonization method and associated software herein. This “recoded” sequence is a non-limiting illustrative example of a sequence that would be generated using an embodiment of the codon optimization method disclosed herein. In some embodiments, publicly available software (e.g., by IDT) can be used to generate a sequence for testing. [0213] Figure 30 shows another embodiment a codon optimized ASL protein coding nucleotide sequence (SEQ ID NO: 21) generated after the harmonization method and associated software herein. [0214] In some embodiments, there will be regions (gaps) where there is additional sequence (resulting in extra amino acids) in one of the two sequences. These codons are not altered from the human cDNA sequence. [0215] In some embodiments, positions where both human and yeast cDNAs encode the same amino acid can be identified. For these amino acid positions, the yeast codon is used. [0216] In some embodiments, codons in the human and yeast cDNAs encode different amino acids at the same position. In this case, the human amino acid is maintained, but where possible its codon is replaced with a codon whose usage frequency closely matches the usage frequency of the yeast codon at that position.. [0217] In some embodiments, for the remaining amino acids positions that align between the two sequences (e.g. not in gaps), it can be checked whether the frequency of codon in humans is comparable to the frequency of that codon in yeast. [0218] If codon usage frequencies is not the same between the two species, then in some embodiments, the codon in the human cDNA can be changed to a codon (for the same amino acid) that is closer to the yeast frequency. In some embodiments, changing one or more codons in the human cDNA to one or more codons (for the same amino acid) that is closer to the yeast frequency results in a robust expression of the human gene in the yeast. [0219] Table 0.4 shows a non-limiting examples of yeast codon usage frequency values. Tables 0.4 and 0.5 can be used in one or more of the condon harmonization methods provided herein. If other organisms are the source or destination, then the appropriate frequencies can be employed. Table 0.4
[0220] Table 0.5 shows a non-limiting examples of human codon usage frequency values. Table 0.5
[0221] In an example, the CAG codon, which encodes Glutamine (Q) and has a high frequency of usage in humans (CAG = 34.6; Table 0.5), can be substituted in a human cDNA to be expressed in yeast with the CAA codon, because CAA, which also encodes Glutamine (Q), has a higher frequency of usage in yeast (27.5; Table 0.4) as compared to CAG (12.2; Table 0.4). [0222] In some embodiments, the gene to be altered is a human gene to be inserted into any one of the following organisms yeast, bacteria, xenopus, insect cells, fish, worms, flies, and/or in vitro cell culture derivatives of any of these organisms. [0223] In some embodiments, the gene to be altered is a plant gene, to be inserted into any one of the following organisms yeast, bacteria, xenopus, insect cells, fish, worms, flies, human cells, and/or in vitro cell culture derivatives of any of these organisms. The plant can be any one or more of fruits, vegetables, flowers, and the like. Additional embodiments Analysis of yeast on solid agar plates [0224] In a first aspect, a method of screening a subject for a disease is provide. The method comprises the steps: obtaining genomic DNA from the subject, identifying a gene of interest from the genomic DNA, inserting the gene into a construct, wherein the construct is a linear DNA, providing a test cell, wherein the test cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the test cell, introducing the construct into the test cell, evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. In some embodiments, the media is solid agar. In some embodiments, the evaluating further comprises quantifying cell growth by photographing yeast growing on solid agar plates and performing image analysis using a custom software. [0225] An analysis may be performed by taking pictures once every 12 hours over the course of 3 days to 5 days, for example. Alternatively, pictures of the agar plates may also be taken every 30 minutes over the course of 3 days. In these cases, at least one time point in that time course (an end point analysis) may be used or several time points may be used to calculate the change in the cell growth over time. [0226] In some embodiments, the media is a liquid media. In some embodiments, the subject is a fetus, neonate, juvenile or adult. In some embodiments, the cell and the control cell are yeast cells. In some embodiments, the amino acid is serine. In some embodiments, the subject is pregnant. In some embodiments, the gene encodes 3-PGDH, PSAT1 or PSPH. In some embodiments, cell growth is measured by optical density. In some embodiments, the evaluating step comprises measuring cell growth for 0.5, 2, 4, 6, 8, 10, 12, 24, 36, 72, 96 or 120 hours or any number of hours in between a range defined by any two aforementioned values. In some embodiments, cell growth of the test cell is comparable to that of the control cell by automated image analysis, wherein the test cell has an optical density that is at least 90% of the growth value of the control cell. In some embodiments, cell growth of the test cell is slow as compared to the control cell, wherein the cell has an optical density that is 79% or less than the optical density of the control cell. In some embodiments, the gene of interest is further analyzed for a single-nucleotide polymorphism. In some embodiments, the single-nucleotide polymorphism is identified as being associated with loss of function or decreased function of a protein encoded by the gene of interest. In some embodiments, a t-test is performed between the test cell and control cell to examine significant growth difference, wherein a t-test p-values < 0.0001 indicates a significant growth difference between the test cell and control cell. In some embodiments, the significant growth difference indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. In some embodiments, the disease is NLS, Serine Deficiency Syndrome or retinal neuropathy. In some embodiments, the evaluating further comprises quantifying cell growth by photographing yeast growing on solid agar plates and performing image analysis using a custom software. Methods and generation of a look up table. [0227] Also contemplated are methods to prepare the look up table in order to generate a prenatal prediction for progeny. The data for predicting a disease in a subject that is a fetus, neonatal, juvenile and adult may be obtained by the methods described herein. This data may be used in a look-up table to predict the phenotypic outcome of a fetus based on the personalized yeast model of both parents and may also be used on a human of any age to determine future health issues, such as adult onset metabolic deficiencies, such as retinal neuropathy. The methods here provide the steps of obtaining genomic DNA from one or two subjects in order to analyze the gene of interest in a test for either haploid cells or diploid cells depending on whether one would like to test one or both of the alleles that have the gene of interest. Thus one can predict the function of a single gene or the effects of having a wild type gene and a mutational recessive as well as a double recessive. The results can then be analyzed to generate a table to correlate certain combinations of genes to a disease and this may be used to develop a therapeutic based on the personalized yeast model results. Measurement of cell growth [0228] In some embodiments, cell growth, may also be referred to as the “growth value”, is measured by optical density of a liquid culture. In some embodiments, cell growth, also the “growth value”, is measured by the area of a “patch” or “spot” of cells growing on solid media, the number of pixels of a “patch” or “spot” of cells growing on solid media, the intensity of the pixels in a “patch” or “spot” of cells growing on solid media, the change in any of these parameters over time, or a combination of any of the afore mentioned parameters. Measurement of the cell growth in a solid media may be measured by photographing yeast growing on solid agar plates and performing image analysis using custom software. Screening a subject for disease [0229] A method of screening a subject for a disease or being a carrier for a disease is provided. The method comprises the steps: obtaining genomic DNA from the subject, identifying a gene of interest from the genomic DNA, inserting the gene into a construct, wherein the construct is a linear DNA, providing a test cell, wherein the test cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the test cell, introducing the construct into the test cell, evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. In some embodiments, the subject is a fetus, neonate, juvenile or adult. In some embodiments, the cell and the control cell are yeast cells. In some embodiments, the amino acid is serine. In some embodiments, the subject is pregnant. In some embodiments, the gene encodes 3-PGDH, PSAT1 or PSPH. In some embodiments, cell growth, hereafter the “growth value”, is measured by optical density of a liquid culture. In some embodiments, cell growth, also the “growth value”, is measured by the area of a “patch” or “spot” of cells growing on solid media, the number of pixels of a “patch” or “spot” of cells growing on solid media, the intensity of the pixels in a “patch” or “spot” of cells growing on solid media, the change in any of these parameters over time, or a combination of any of the aforementioned parameters. In some embodiments, the evaluating step comprises measuring cell growth for 0.5, 2, 4, 6, 8, 10, 12, 24, 36, 72, 96 or 120 hours or any number of hours in between a range defined by any two aforementioned values. In some embodiments, growth of the test cell is comparable to that of the control cell by automated image analysis, wherein the test cell has a growth value that is at least 90% of the growth value of the control cell. In some embodiments, cell growth of the test cell is slow as compared to the control cell, wherein the cell has an optical density or growth value that is 79% or less than the growth value of the control cell. The measurement may be performed by analyzing cell growth on a solid media, thus the measurement is performed by analysis of pixels in a “patch” or “spot” of cells growing on solid media, the change in any of these parameters over time. This cell growth can be measured against a control cell that is carrying a wild type PSAT1 gene. The growth is measured to find thresholds for a severe form of a metabolic disease (e.g. NLS). Milder forms of the disease such as adult onset diseases are likely to have a different threshold than those suffering from a severe form of the disease. [0230] In some embodiments, the gene of interest is further analyzed for a single- nucleotide polymorphism. In some embodiments, the single-nucleotide polymorphism is identified as being associated with loss of function or decreased function of a protein encoded by the gene of interest. In some embodiments, a t-test is performed between the test cell and control cell to examine significant growth difference, wherein a t-test p-values < 0.0001 indicates a highly significant growth difference between the test cell and control cell. In some embodiments, the significant growth difference indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. In some embodiments, the disease is NLS, Serine Deficiency Syndrome or retinal neuropathy. In some embodiments, the evaluating further comprises quantifying cell growth by photographing yeast growing on solid agar plates and performing image analysis using custom software. [0231] Cell growth, may also be referred to as the “growth value”, and may be measured by optical density of a liquid culture. In some embodiments, cell growth, also the “growth value”, is measured by the area of a “patch” or “spot” of cells growing on solid media, the number of pixels of a “patch” or “spot” of cells growing on solid media, the intensity of the pixels in a “patch” or “spot” of cells growing on solid media, the change in any of these parameters over time, or a combination of any of the aforementioned parameters. [0232] [0274] The biochemical pathway that produces serine is nearly identical between humans and yeast. Loss of function mutations in any of the three serine biosynthetic genes in humans cause Serine Deficiency Syndrome. In yeast, loss of function of the yeast enzymes produces a quantitative and easily measured trait, poor growth in the absence of serine supplementation. In the embodiments herein, it is shown that the human protein coding sequence of the PSAT1 gene can functionally replace the corresponding SER1 gene in yeast. Thus the yeast-based assay described in the embodiments for measuring the activity of PSAT1 gene variants found in a specific patient may be used as part of the protocol for assessing the clinical significance of a genetic variant (Richards, S., et al., Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in medicine : official journal of the American College of Medical Genetics 17, 405-424, 2015, which is hereby incorporated by reference in its entirety) or for other types of genetic analyses, such as genome-wide association studies (GWAS).. [0233] In a first aspect, a method of screening a subject for a disease is provided. The method comprises the steps: obtaining genomic DNA from the subject, identifying a gene of interest from the genomic DNA, inserting the gene into a construct, wherein the construct is a linear DNA, providing a test cell, wherein the test cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the test cell, introducing the construct into the test cell, evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. In some embodiments, the subject is a fetus, neonate, juvenile or adult. In some embodiments, the cell and the control cell are yeast cells. In some embodiments, the amino acid is serine. In some embodiments, the subject is pregnant. In some embodiments, the gene encodes 3-PGDH, PSAT1 or PSPH. In some embodiments, cell growth is measured by optical density of a liquid culture, or a number of pixels of a colony of cells growing on solid media.. In some embodiments, wherein the evaluating step comprises measuring cell growth for 0.5, 2, 4, 6, 8, 10, 12, 24, 36, 72, 96 or 120 hours or any number of hours in between a range defined by any two aforementioned values. In some embodiments, growth of the test cell is comparable to that of the control cell by automated image analysis, wherein the test cell has a growth value that is at least 90% of the growth value of the control cell. In some embodiments, cell growth of the test cell is slow as compared to the control cell, wherein the cell has an optical density that is 79% or less than the growth value of the control cell. In some embodiments, the gene of interest is further analyzed for a single-nucleotide polymorphism. In some embodiments, the single-nucleotide polymorphism is identified as being associated with loss of function or decreased function of a protein encoded by the gene of interest. In some embodiments, a t-test is performed between the test cell and control cell to examine significant growth difference, wherein a t-test p-values < 0.0001 indicates a highly significant growth difference between the test cell and control cell. In some embodiments, the significant growth difference indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. In some embodiments, the disease is NLS, Serine Deficiency Syndrome or retinal neuropathy. In some embodiments, the evaluating further comprises quantifying cell growth by photographing yeast growing on solid agar plates and performing image analysis using custom software. [0234] In a second aspect, a method of determining amino acid deficiency in a subject is provided. The method comprises the steps: isolating genomic DNA from a subject, detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway, inserting the gene into a construct, introducing the construct into a test cell, growing up the cell in a media absent of an amino acid and analyzing growth of the test cell in a culture, wherein the growth of the test cell is compared to a control cell, wherein the control cell is not deficient in amino acid synthesis wherein the test cell growth is compared to the control cell, wherein cell growth of the test cell is comparable to that of the control cell indicates that the gene encodes a functional enzyme and wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene encodes a non- functional protein or protein with decreased function and indicates The method of claim 1, wherein the subject is a fetus, neonate, juvenile or adult. In some embodiments, the cell and the control cell are yeast cells. In some embodiments, the amino acid is serine. In some embodiments, the subject is pregnant. In some embodiments, the gene encodes 3-PGDH, PSAT1 or PSPH. In some embodiments, cell growth is measured by optical density. In some embodiments, the analyzing step comprises measuring cell growth for 0.5, 2, 4, 6, 8, 10, 12, 24, 36, 72, 96 or 120 hours or any number of hours in between a range defined by any two aforementioned values. [0235] In some embodiments, a patient DNA is not required and the only information required is what sequence polymorphisms the patient has. In some embodiments, such information can be obtained from clinical geneticists, the scientific literature, or public and private databases. [0236] In some embodiments, cell growth of the test cell is comparable to that of the control cell by automated image analysis, wherein the test cell has a growth value that is at least 90% of the growth value of the control cell. In some embodiments, cell growth of the test cell is slow as compared to the control cell, wherein the cell has a growth value that is 79% or less than the optical density of the control cell. [0237] In some embodiments, the gene of interest is further analyzed for a single- nucleotide polymorphism. In some embodiments, the single-nucleotide polymorphism is identified as being associated with loss of function or decreased function of a protein encoded by the gene of interest. [0238] In some embodiments, a t-test is performed between the test cell and control cell to examine significant growth difference, wherein a t-test p-values < 0.0001 indicates a highly significant growth difference between the test cell and control cell. In some embodiments, the significant growth difference indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. [0239] In some embodiments, the disease is NLS, Serine Deficiency Syndrome or retinal neuropathy or an amino acid deficiency in the subject. [0240] In some embodiments, the analyzing step further comprises identifying at least one mutation in the gene. [0241] In a third aspect, a method of determining a carrier of an amino acid deficiency disorder is provided. The method comprises the steps: isolating genomic DNA from a subject, detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway, wherein the subject has two different alleles of the gene, inserting the gene into a construct, wherein the construct is a linear DNA, introducing the construct into a test cell, growing up the test cell in a media absent of an amino acid and evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein test cell growth is compared to a control cell that has the homologous gene, wherein test cell growth of the cell is comparable to that of the control cell indicates that the gene of interest encodes a functional protein and wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene of interest encodes a non- functional protein or protein with decreased function and indicates that the subject is a carrier of an amino acid deficiency disorder. In some embodiments, the amino acid deficiency disorder is NLS. [0242] In a fourth aspect, a method of treating a subject with an amino acid deficiency is provided. The method comprises the steps: determining a subject or carrier of an amino acid deficiency disorder, wherein the determining comprises: detecting a gene from the genomic DNA, wherein the gene encodes an enzyme of an amino acid synthesis pathway; inserting the gene into a construct, wherein the construct is a linear DNA; introducing the construct into a test cell; growing up the test cell in a media absent of an amino acid; and evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein test cell growth is compared to a control cell that has the homologous gene, wherein cell growth of the test cell is slow as compared to the control cell indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates that the subject is a carrier of an amino acid deficiency disorder; and providing an adequate amount of an amino acid supplement to the subject. In some embodiments, the amino acid supplement is serine. In some embodiments, the enzyme is wherein the gene encodes 3-PGDH, PSAT1 or PSPH. In some embodiments, the subject is a fetus and wherein the mother of the fetus is provided an adequate amount of amino acid supplement. In some embodiments, the evaluating further comprises comparing growth of the test cell to a second control cell, wherein the second control cell is deficient in serine biosynthesis. In some embodiments, the amino acid deficiency disorder is NLS. [0243] In a fifth aspect, a method of prenatal prediction of an amino acid deficiency is provided. The method comprises the steps: a) obtaining genomic DNA from a female and male subject, identifying a same gene of interest from the genomic DNA of the female and male subject, wherein the subjects are homozygous or heterozygous for the gene, inserting a first gene variant of interest from the female into a first construct, wherein the first construct is a linear DNA, inserting a second gene variant of interest from the male into a second construct, wherein the second construct is a linear DNA, providing a first cell, wherein the first cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell, providing a second cell, wherein the second cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell, introducing the first construct into the first cell, wherein the first construct is a linear DNA, introducing the second construct into the second cell, wherein the second construct is a linear DNA and evaluating the first and second cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the first and second cell are compared to a control cell that has the homologous gene, wherein cell growth of the first and/or second cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the first and second cell is slow as compared to the control cell indicates that the first and second gene of interest encodes a non-functional protein or protein with decreased function and indicates that the male and/or female is a carrier of a disease for an amino acid deficiency. In some embodiments, the method further comprises making a diploid strain of a third cell, wherein the third cell comprises the first and second gene of interest and evaluating the third cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the third cell are compared to a control cell that has the homologous gene, wherein cell growth of the third cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the third cell is slow as compared to the control cell indicates that the first and second gene of interest together indicates a predicted fetus with an amino acid deficiency. In some embodiments, data from the first, second and third cell is stored in a look-up table, wherein the look-up table is generated for disease prediction. In some embodiments, the disease for an amino acid deficiency is NLS. [0244] In a sixth aspect, a method of method of prenatal prediction of an amino acid deficiency wherein at least one parent has a gene mutation is provided. The method comprises the steps: obtaining genomic DNA from a female and male subject, identifying a same gene of interest from the genomic DNA of the female and male subject, wherein the subjects are homozygous or heterozygous for the gene, inserting a first gene of interest from the female into a first construct, inserting a second gene of interest from the male into a second construct, providing a first cell, wherein the first cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell, providing a second cell, wherein the second cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the cell, making a diploid strain of a third cell, wherein the third cell comprises the first and second gene of interest, introducing the first construct into the first cell, wherein the first construct is a linear DNA, introducing the second construct into the second cell, wherein the second construct is a linear DNA and evaluating the first, second, and third cell for cell growth in a media, wherein the media lacks an amino acid, wherein the cell growth of the first and second cell are compared to a control cell that has the homologous gene, wherein cell growth of the first, second and third cell is comparable to that of the control cell indicates that the first and second gene of interest encodes a functional protein and wherein cell growth of the first, second and third cell is slow as compared to the control cell indicates that the first and second gene of interest encodes a non-functional protein or protein with decreased function and predicts an amino acid deficiency for progeny. In some embodiments, the first gene of interest or the second gene of interest comprises the gene mutation. In some embodiments, the gene of interest encodes PSAT. In some embodiments, the gene of interest encodes PSAT1 with at least one of the amino mutations A99V, S179L, T156M, G78A, R213C or R222. In some embodiments, data from the first, second and third cell is stored in a look-up table, wherein the look-up table is generated for disease prediction. In some embodiments, the amino acid deficiency is caused by NLS. [0245] In a seventh aspect, a kit for determining amino acid deficiency is provided. The kit comprises a look-up table, wherein the look up table indicates genes or combinations of genes that may be indicative of an amino acid deficiency or disease, one or more nucleic acid probes for detecting one or more mutation in PSAT, wherein the one or more mutation includes at least: G78A, R213C, T156M or R222. In some embodiments, the kit comprises a serine supplement in an amount sufficient to treat a subject suffering from serine deficiency. [0246] In an eighth aspect, a method of determining if a subject is suffering from an amino acid deficiency is provided. The method comprises the steps: providing a look-up table, wherein the look-up table comprises genes or a combination of genes that are indicative of a disease, isolating genes of interest from a subject, determining if the genes include one of more mutations in the look-up table and determining a probability of disease in the subject. In some embodiments, the look up table comprises combination of genes that include genes of PSAT, wherein the PSAT genes encode PSAT comprising mutations G78A, R213C, T156M or R222. In some embodiments, the look up table comprises a list of mutations that have been determined by the method of claim 43, said method further comprising administering an amino acid supplement to the subject to treat the amino acid deficiency if the subject has more than a 50% probability of having the amino acid deficiency. [0247] In a ninth aspect, a method of treating a subject with an amino acid deficiency is provided. The method comprises the steps: determining if a subject has at least one mutation in PSAT located at G78, R213, T156 or R222 and providing an adequate amount of a serine supplement to the subject if the subject has the at least one mutation. In some embodiments, the at least one mutation is G78A, R213C, T156M or R222, and wherein the subject is an unborn child of a mother, wherein the mother is tested for the presence of the at least one mutation. [0248] In a tenth aspect, a method of identifying a point mutation as a cause or marker of an amino acid deficiency is provided. The method comprises the steps: obtaining genomic DNA from a subject having the amino acid deficiency, identifying a point mutation in the genomic DNA in at least one of 3-PGDH, PSAT1 or PSPH, providing a test yeast cell, wherein a homologous gene of at least one of 3-PGDH, PSAT1 or PSPH has been knocked out of the test yeast cell, introducing the gene with the point mutation into the test yeast cell and evaluating the test yeast cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test yeast cell growth is compared to a control cell that has the homologous gene, wherein when test yeast cell growth is comparable to that of the control cell it indicates that the point mutation still allows for a functional protein, and wherein when the test yeast cell growth is slow as compared to the control cell it indicates that the point mutation results in a non-functional protein or protein with decreased function, thereby identifying the point mutation as a cause or marker of an amino acid deficiency. [0249] In an eleventh aspect, a method of preparing a personalized yeast model for determining a subject at risk of a disease is provided. The method comprises the steps: obtaining genomic DNA from the subject, identifying a gene of interest in at least two alleles from the genomic DNA, inserting the gene into a construct, wherein the construct is a linear DNA;, providing a test cell, wherein the test cell has a homologous gene of the gene of interest, wherein the homologous gene has been knocked out of the test cell, introducing the construct into the test cell, evaluating the test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease, generating data for a look-up table; and generating one or more personalized disease amelioration recommendations for the subject; and presenting the one or more personalized disease prevention recommendations for the subject in the personalized disease prevention plan for the subject for disease management. In some embodiments, the method further comprising: a) obtaining a second genomic DNA from a second subject, wherein the second subject has a second set of two alleles that are related to the two alleles of the subject, and second set of two alleles have a second gene of interest, wherein the second gene of interest is placed in a second construct b) introducing the second construct into a second test cell, evaluating the second test cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when second test cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein and wherein when the test cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non- functional protein or protein with decreased function. In some embodiments, the method further comprises obtaining a second genomic DNA from a second subject and identifying a second gene(s) of interest in at least two alleles from the genomic DNA, inserting at least one of the second gene(s) into a second construct, introducing the second construct into a second test cell, and mating the second cell with the first cell to produce a progeny cell. In some embodiments, the method further comprises evaluating the progeny cell for cell growth in a media, wherein the media lacks an amino acid, wherein the test cell growth is compared to a control cell that has the homologous gene, wherein when progeny cell growth is comparable to that of the control cell it indicates that the gene of interest encodes a functional protein, and wherein when the progeny cell growth is slow as compared to the control cell it indicates that the gene of interest encodes a non-functional protein or protein with decreased function and indicates the disease. Additional sequences [0250] PSAT1_codon_optimized integrating plasmid [0251] 1-1342= pUC19 vector backbone [0252] 1336-1343 and 4759-4764 (bolded)= SapI and SnaBI restriction sites used to liberate construct for integration [0253] 1343-1438 (italics)= sequence 5’ of SER1 start codon to direct integration [0254] 1439-2551 (underl PSAT1 open reading frame that has been codon optimized for expression in Saccharom yces cerevisiae. [0255] 2552-3014 (bolded italics)= Sequence 3’ of SER1 stop codon that includes SER1 terminator sequence [0256] 3015-4520 (lower case)= kanMX drug marker [0257] 4521-4761 (italics)= sequence 3’ of SER1 terminator to direct integration [0258] 4762-6097 (capital letters)= pUC19 vector backbone [0259] AB481 or pAS19-PSAT1-K sequence (SEQ ID NO: 3) GCACCAGTTATAA Examples [0260] The following examples are non-limiting and additional variants contemplated by one having ordinary skill in the art are encompassed within the scope of this disclosure. Example 1. Assays for determination of PSAT variant function [0261] As shown in Figure 2, the human protein coding sequence of the PSAT1 gene can functionally replace the corresponding SER1 gene in yeast. This single copy can be stably integrated into the genome under the control of the native yeast regulatory sequences for transcription, translation, and mRNA stability with the nucleic acid comprising the sequence as shown in Figure 2. This strategy can be applied to any metabolic enzyme, not just the serine pathway, by using the protein coding sequence for any metabolic enzyme in the construct in Fig.2. [0262] The PSAT1 sequence was codon optimized for expression in yeast (SEQ ID NO: 1: ATGGACGCGCCAAGACAGGTTGTGAATTTCGGACCTGGGCCAGCTAAATTGCCT
[0263] For frameshift mutations an optimized sequence was used up to the mutation. After the SNP, the human cDNA sequence, SEQ ID NO: 2, was used. (SEQ ID NO: 2:
[0264] In some embodiments, the PSAT1 is encoded by a gene comprising a sequence set forth in SEQ ID NO: 3. [0265] Cells were grown in liquid rich yeast medium (YPD) broth that contains serine. Cells expressing the wild type SER1 (yeast homolog of PSAT1), no gene, PSAT1, PSAT1 mutant A99V, PSAT1 mutant S179L, were used to inoculate (by replica pinning) prepared solid agar plates containing yeast minimal medium (SD), which lacks serine. Growth of each strain, which contains a PSAT1 variant or a control (e.g. the yeast SER1 gene or a ser1 deletion), was quantified by photographing the yeast growing on the solid agar plates and performing image analysis using custom software (written by the inventors). The assays include technical and biological replicates. As shown, the loss of function of the yeast enzymes produces a quantitative and easily measured trait, poor growth in the absence of serine supplementation. In the example below, it is shown that the human protein coding sequence of the PSAT1 gene can functionally replace the corresponding SER1 gene in yeast. This gives a yeast-based assay for measuring the activity of PSAT1 gene variants found in a specific patient, a genome-wide association study (GWAS), or the population at large. (Figure 3). As shown, is the growth in the absence of serine, for wildtype strain (“yeast gene”), a SER1 deletion (“no gene”) or strains with human PSAT1 coding sequence or two human disease gene variants (A99V and S179L, respectively). A t-test between “yeast gene” and “human gene” growth was not significant (N.S.) The growth conferred by variants 1 and 2 (disease alleles were significantly below that of the human gene (t-test p-values < 0.0001, ***). There was no significant difference between a gene deletion and variant 2, suggesting that variant 2 is equivalent to a complete loss of function. The tests on the yeast strains may be performed on either agar plates or in a liquid media. [0266] Assays were performed to assess the function of genes that were determined by computational methods to be either functional or non-functional (Figure 4). Tests were performed on PSAT proteins with the mutations: 1) K110Q, 2) V149M, 3) T156M, 4) R222*, 5) N236H 6) V250A. As shown in the table (Figure 4, right panel), PSAT proteins with the mutations K110Q and V149M were determined to be deleterious proteins. PSAT proteins with the mutations N236H and V250A were considered to be “neutral” while T156M and R222 were predicted to be deleterious or with an undetermined function, respectively. [0267] Assays for PSAT1 protein functions were performed on PSAT1 proteins with the mutations 1) K110Q, 2) V149M, 3) T156M, 4) R222, 5) N236H 6) V250A to determine protein function as compared to the predicted protein characteristics as determined by the computational methods (Figure 4, right panel). As shown in the left panel of Figure 4, the mutants K110Q, V149M, N236H and V250A were shown to have growth that was comparable to the growth of the wild type PSAT1 protein. The PSAT proteins with the mutations T156M and R222 were shown to be deleterious by this method. Thus the assay provides a fast diagnostic to show the functionality of a protein which cannot be predicted by a computational analysis. [0268] The assay can be used to perform tests on individual alleles as well. As shown in Figure 6, additional mutants were also tested for their performance in media that was lacking in serine. As shown, the PSAT mutants with a G78A and R213C mutation were compared to the growth of cells expressing PSAT1 (control), A99V, D100, and S179. These proteins were previously predicted to be variable unknowns. As shown is the growth data of the three known human disease gene variants (A99V, D100A and S179L), and suspected pathogenic variants that were classified as variable outcome strains (S179L and G78A). As shown, the S179L and G78A mutants have growth comparable to null alleles. [0269] Cell growth, may also be referred to as the “growth value”, and may be measured by optical density of a liquid culture. In some embodiments, cell growth, also the “growth value”, is measured by the area of a “patch” or “spot” of cells growing on solid media, the number of pixels of a “patch” or “spot” of cells growing on solid media, the intensity of the pixels in a “patch” or “spot” of cells growing on solid media, the change in any of these parameters over time, or a combination of any of the aforementioned parameters. Example 2: Assays for personalized yeast models for affected individuals and carriers [0270] Diploid strains carrying PSAT1/PSAT1, PSAT1/A99V and PSAT1/S179L were prepared. These diploid strains were prepared by mating haploid cells each containing one of the two variants, e.g. A99V and S179L. The resulting diploid cell is heterozygous for the two variants. Homozygous diploid strains and strains that are heterozygous for a wildtype and mutant version of the gene, e.g. PSAT1/A99V, are made in the same way. The yeast cells were then analyzed for growth in YPD media that lacked serine. This test may also be performed in agar plates or liquid media for assessment of cell growth. As shown in Figure 8, the diploid cells PSAT1/A99V and PSAT1/S179L were shown to function above the pathogenic threshold, which indicates that the protein is predicted to be functional, however the proteins have reduced activity as compared with the PSAT1/PSAT1 homozygous. The pathogenic threshold may be calculated for different heterozygotes. Crossing cells to generate a heterozygous A99V/S179L was performed to test the heterozygote for growth in media lacking serine. As shown in the graph, the heterozygous A99V/S179L produced a PSAT1 protein with decreased function which was predicted to lead to a pathogenic phenotype in a progeny carrying both the A99V and the S179L genes. As such, the data generated from the assays may be used to determine a threshold for disease and may be used to create personalized data prediction of disease, prediction of adult onset of a disease and prediction of disease of progeny for two subjects. An example of a personalized test is shown in Figure 7. As shown in Figure 7, is a test of diploid strains. The control is homozygous for PSAT1. The two parents are heterozygous for PSAT1/A99V and PSAT1/179L. As shown the progeny is a carrier of the A99V and the S179L mutation. The protein expressed by the progeny has decreased function as compared to the parent strains as well as the control cell. [0271] Cell growth, may also be referred to as the “growth value”, and may be measured by optical density of a liquid culture. In some embodiments, cell growth, also the “growth value”, is measured by the area of a “patch” or “spot” of cells growing on solid media, the number of pixels of a “patch” or “spot” of cells growing on solid media, the intensity of the pixels in a “patch” or “spot” of cells growing on solid media, the change in any of these parameters over time, or a combination of any of the aforementioned parameters. Example 3: Assessment of diploid yeast strains carrying PSAT mutations for personalized model systems [0272] As shown in Figure 9, the growth values of several haploids in the absence of serine for haploid strains containing the PSAT1 variants listed above each bar. The cells are grown in the methods previously described in which the media is lacking the essential amino acid, serine. From left to right is PSAT (control), A15V, A99V, c.delG107, D100A, D145Mfs*49, G78A, R213C, R342Dfs*6, S179L, S43R and S43R. N is the number of replicates. Y is the median growth value. NS or asterisks indicate the results of t-tests between a variant and PSAT1 (control). These are all alleles that have been associated with disease in the literature. A15V, A99V, c.delG107, D100A, D145Mfs*49 and S179L are considered in the literature as being pathogenic, G78A, R213C and S43R are annotated as variants of uncertain significance (VUS). As shown, the haploid cells carrying the mutant PSAT1 gene have a decreased function, with the significant lack of function is shown for mutants c.delG107, D145Mfs*49, G78A, R342Dfs*6 and S179L. [0273] Tests were then performed on diploid strains in order to examine the progeny cells that may carry at least one mutation in a diploid strain. As shown in Figures 10-18, the mutants as described in Figure 5, were used to examine the effects of having either one or two recessive genes that were shown to effect the growth of cells in a serine- free media. [0274] As shown in Figure 10, is a personalized yeast model for an affected patient and carrier parents (PSAT x D100A and c.delG107 x D100A). As shown in Figure 10, the progeny has two PSAT alleles (delG107 x D100A) that leads to a protein with decreased function. Thus a patient with this genotype, may need to be provided with a therapy that involves supplementation of the amino acid in order to have normal cellular functions. [0275] As shown in Figure 11, is a personalized yeast model for an affected patient with the carrier parents that both have the allele for a wild type PSAT1 gene and Arg342Aspfs gene. As shown, the progeny (3) has two PSAT alleles (Arg342Aspfsכ6 x Arg342Aspfsכ6) that leads to a protein with loss of function. Thus a patient with this genotype, may need to be provided with a therapy that involves supplementation of the amino acid in order to have normal cellular functions. As this test may be performed on individuals who are expecting, Determining a fetus with this genotype, one may need to provide with a therapy for a pregnant subject that involves supplementation of the amino acid in order to have normal cellular functions in a fetus. [0276] As shown in Figure 12, is a personalized yeast model for an affected patient with the carrier parents that both have the allele for A99V and the wild type PSAT1 gene. As shown, the progeny (3) has two PSAT1 alleles (A99V x A99V) that leads to a protein with decreased function. Thus a patient with this genotype, may need to be provided with a therapy that involves supplementation of the amino acid in order to have normal cellular functions. [0277] As shown in Figure 13, is a personalized yeast model for an affected patient with the carrier parents that both have the allele PSAT1 gene and gene for the PSAT1 with the S179L mutation. As shown in Figure 13, the progeny (3) has two PSAT1 alleles (S179L x S179L) that leads to a protein with complete loss of function. As this test may be performed on individuals who are expecting, Determining a fetus with this genotype, one may need to provide with a therapy for a pregnant subject that involves supplementation of the amino acid in order to have normal cellular functions in a fetus. This test may also be performed for genetic testing for a couple in order to determine their probability of having a child with a metabolic disease. [0278] As shown in Figure 14, is a personalized yeast model for an affected patient with the carrier parents that both are heterozygous for the wild type PSAT1 and a recessive PSAT1 mutant gene (PSAT1 x S179L and A99V x PSAT1). As shown, the progeny (4) has two PSAT alleles (A99V x S179L) that leads to a protein with decreased function. Thus a patient with this genotype, may need to be provided with a therapy that involves supplementation of the amino acid in order to have normal cellular functions. [0279] As shown in Figure 15, is a personalized yeast model for an affected patient with the carrier parents that both are heterozygous for the wild type PSAT1 and a recessive PSAT1 mutant gene. (both parents: S43R x PSAT1). As shown in Figure 15, the progeny (3) has two PSAT1 alleles (S43R x S43R) that leads to a protein that’s comparatively as functional as the parent. Thus assessment of the health of the patient will need to be evaluated to determine if serine supplementation is needed. [0280] A personalized yeast model was also performed for parents that have the alleles for PSAT1 with the G78A mutation and the wild type PSAT1. As shown in Figure 16, the progeny (3) has two PSAT1 alleles (G78A x G78A) that leads to a protein has a complete loss of function as compared to the parent and the wild type. [0281] A personalized yeast model was also performed for parents that have the alleles for PSAT1 with the R213C mutation and the wild type PSAT1. As shown in Figure 17, the progeny (3) has two PSAT1 alleles (R213C x R213C) that leads to a protein has decreased function as compared to the parent and the wild type. [0282] As shown in Figure 18, a personalized yeast model was also performed for two heterozygous parents that have the alleles for PSAT1 x A15V and D145Mfs*49 x PSAT100. The progeny (4) has two PSAT alleles (D145Mfs*49 x A15V) that lead to a protein with decreased function as compared to the wild type. However, the progeny does have similar protein characteristics with one of the parents (Bar 3), this may possibly show that one mutant is dominant over the other. [0283] In view of the personalized tests, it is envisioned that one would be enabled to predict the types of alleles a child would receive from their parents as well as the outcomes for each case. For example, one would be able to predict if a certain mutation was dominant over another (such as the example shown in Figure 18), which could possibly lead to a protein that has more function than a child with two recessive alleles (as shown in Figures 16 and 17). Thus a model can be created for prospective parents that would let one know the probability of having a child that had both PSAT1 wild type genes as well, two recessive mutant genes, and possible outcomes of the heterozygotes. Thus one would have the ability to develop a therapeutic or prepare an early intervention such as a dietary plan with supplements to prevent neonatal problems or prevent adult onset of a disease. Example 4 - Yeast model for arginine biosynthesis pathway [0284] The yeast enzymes in three colinear steps of the arginine biosynthesis pathway are highly conserved with their human orthologs (Table 1). In humans, this pathway is known as the urea cycle because it is the principal mechanism for the clearance of waste nitrogen resulting from protein turnover and enzyme deficiencies cause urea cycle disorders [1, 2]. [0285] In order to test whether yeast models could be established for the human urea cycle pathway, the corresponding yeast orthologs of OTC, ASS1, and ASL were replaced with the wildtype human ORF or a variant containing a published early onset disease allele (otc-R141Q [3], ass1-R127W [4], asl-Q286R [5]). Functional assays were performed on sequence confirmed biological replicates as described for PSAT1 (Figure 1), except with minimal medium lacking arginine as the condition-specific growth assay. Previous studies had successfully introduced OTC [6] and ASL [5] into yeast, although both were overexpressed from high copy plasmids and a strong galactose-inducible promoter. In this experiment (Figure 19), the human protein coding sequences conferred condition-specific growth at 82% (OTC), 87% (ASS1), and 93% (ASL) of the growth conferred by their respective yeast orthologs, and the disease alleles showed statistically significant growth defects (Student’s t-test, p<0.001). The custom codon optimization method described herein in Example 5 (based on codon usage frequency) substantially improved the degree to which OTC and ASS1 were able to complement loss of their yeast orthologs. The human ASS1 cDNA sequence only conferred growth at 49% of that of the yeast ortholog, and for OTC, our codon optimization method resulted in better complementation than codon optimization by IDT (82% versus 54%). Example 5 - Codon harmonization method [0286] Figure 20 show an embodiment of a Codon harmonization method described herein. Human cDNA and yeast cDNA sequences (both products of nature) for two orthologous genes were aligned. There will often be regions (gap, gray) where there is additional sequence (resulting in extra amino acids) in one of the two sequences. Positions where both cDNAs encode the same amino acid were identified (*) and the codons in the human cDNA were replaced with the yeast codon used at that position in the alignment (yellow bars), if the human and yeast codons were different. For the remaining amino acids positions that align between the two sequences (e.g., not in gaps), it was checked whether the frequency of codon in humans is comparable to the frequency of that codon in yeast. If codon usage frequencies were not the same between the two species, the codon in the human cDNA was changed to a codon (for the same amino acid) that is closer to the yeast frequency (green). Example 6 [0287] Reverse harmonization for codon optimization is performed by obtaining a sequence of a first gene/cDNA to be optimized from a first organism; obtaining a sequence of a second gene/cDNA from a second organism, wherein the second gene/cDNA is an ortholog of the first gene/cDNA, and the first gene/cDNA is to be optimized for expression in the second organism; performing a first alignment of the first and second gene/cDNA sequences; obtaining a protein sequence encoded by the a first gene/cDNA; obtaining a protein sequence encoded by the second gene/cDNA; performing a second alignment of the protein sequences encoded by the firs tan d second gene/cDNA; identifying positions in the first alignment where codons that mutually correspond to each other in the first and second gene/cDNA sequences encode the same amino acid at mutually corresponding positions in the second alignment; and replacing the codon in the first gene/cDNA with the codon in the second gene/cDNA, if the codons in the first and second gene/cDNA that encode the same amino acid at mutually corresponding positions in the second alignment are different between the first and second gene/cDNA, thereby obtaining a codon optimized first gene/cDNA from the first organism. Positions in the first alignment are identified where codons differ between the first and the second genes/DNA; and replaced with codons in the first gene/cDNA lacking corresponding codons in the second gene/cDNA by selecting codons from the second organism that encode the same amino acid. Codon from the second organism are selected based on a frequency of usage of a codon encoding a particular amino acid in the second organism. Following codon optimization by reverse harmonization, a protein encoded by the codon optimized first gene/cDNA is expressed more efficiently and/or at a higher level in the second organism as compared to a codon non-optimized first gene/cDNA. Example 7 [0288] Reverse harmonization for codon optimization is performed by obtaining a sequence of a human gene/cDNA to be optimized from a human; obtaining a sequence of a yeast gene/cDNA from a yeast, wherein the yeast gene/cDNA is an ortholog of the human gene/cDNA, and the human gene/cDNA is to be optimized for expression in the yeast; performing a first alignment of the human and yeast gene/cDNA sequences; obtaining a protein sequence encoded by the human gene/cDNA; obtaining a protein sequence encoded by the yeast gene/cDNA; performing a second alignment of the protein sequences encoded by the human and yeast gene/cDNA; identifying positions in the first alignment where codons that mutually correspond to each other in the human and yeast gene/cDNA sequences encode the same amino acid at mutually corresponding positions in the second alignment; and replacing the codon in the human gene/cDNA with the codon in the yeast gene/cDNA, if the codons in the human and yeast gene/cDNA that encode the same amino acid at mutually corresponding positions in the second alignment are different between the human ad yeast gene/cDNA, thereby obtaining a codon optimized human gene/cDNA. Positions in the first alignment are identified where codons in the human gene/cDNA lack corresponding codons in the yeast gene/cDNA sequences; and replaced with codons in the human gene/cDNA lacking corresponding codons in the yeast gene/cDNA by selecting codons from the yeast that encode the same amino acid. Codon from the yeast are selected based on a frequency of usage of a codon encoding a particular amino acid in the yeast. Following codon optimization by reverse harmonization, a protein encoded by the codon optimized human gene/cDNA is expressed more efficiently and at a higher level in the yeast as compared to a codon non-optimized human gene/cDNA. Example 8 [0289] Reverse harmonization for codon optimization is performed by obtaining a sequence of one or more of the sequences shown in Table 2 (Gene X) to be optimized; obtaining a sequence of a vegetable gene/cDNA from a vegetable, wherein the vegetable gene/cDNA is an ortholog of Gene X, and Gene X is to be optimized for expression in the vegetable; performing a first alignment of Gene X and the vegetable gene/cDNA sequences; obtaining a protein sequence encoded by Gene X; obtaining a protein sequence encoded by the vegetable gene/cDNA; performing a second alignment of the protein sequences encoded by Gene X and the vegetable gene/cDNA; identifying positions in the first alignment where codons that mutually correspond to each other in Gene X and vegetable gene/cDNA sequences encode the same amino acid at mutually corresponding positions in the second alignment; and replacing the codon in Gene X with the codon in the vegetable gene/cDNA, if the codons in Gene X and vegetable gene/cDNA that encode the same amino acid at mutually corresponding positions in the second alignment are different between Gene X and the vegetable gene/cDNA, thereby obtaining a codon optimized Gene X. Positions in the first alignment are identified where codons in Gene X lack corresponding codons in the vegetable gene/cDNA sequences; and replaced with codons in Gene X lacking corresponding codons in the vegetable gene/cDNA by selecting codons from the vegetable that encode the same amino acid. Codon from the vegetable are selected based on a frequency of usage of a codon encoding a particular amino acid in the vegetable. Following codon optimization by reverse harmonization, a protein encoded by the codon optimized Gene X is expressed more efficiently and at a higher level in the vegetable as compared to a codon non-optimized Gene X. Example 9 [0290] Reverse harmonization for codon optimization is performed by obtaining a sequence of one or more of the sequences shown in Table 2 (Gene Y) to be optimized; obtaining a sequence of a pet gene/cDNA from a pet (e.g., cat, dog, hamster, and the like), wherein the pet gene/cDNA is an ortholog of Gene Y, and Gene Y is to be optimized for expression in the pet; performing a first alignment of Gene Y and the pet gene/cDNA sequences; obtaining a protein sequence encoded by Gene Y; obtaining a protein sequence encoded by the pet gene/cDNA; performing a second alignment of the protein sequences encoded by Gene Y and the pet gene/cDNA; identifying positions in the first alignment where codons that mutually correspond to each other in Gene Y and pet gene/cDNA sequences encode the same amino acid at mutually corresponding positions in the second alignment; and replacing the codon in Gene Y with the codon in the pet gene/cDNA, if the codons in Gene Y and pet gene/cDNA that encode the same amino acid at mutually corresponding positions in the second alignment are different between Gene Y and the pet gene/cDNA, thereby obtaining a codon optimized Gene Y. Positions in the first alignment are identified where codons in Gene Y lack corresponding codons in the pet gene/cDNA sequences; and replaced with codons in Gene Y lacking corresponding codons in the pet gene/cDNA by selecting codons from the pet that encode the same amino acid. Codon from the pet are selected based on a frequency of usage of a codon encoding a particular amino acid in the pet. Following codon optimization by reverse harmonization, a protein encoded by the codon optimized Gene Y is expressed more efficiently and at a higher level in the pet as compared to a codon non-optimized Gene Y. Example 10 [0291] Reverse harmonization for codon optimization is performed by obtaining a sequence of one or more of the sequences shown in Table 2 (Gene Z) to be optimized; obtaining a sequence of a yeast gene/cDNA from a yeast, wherein the yeast gene/cDNA is an ortholog of Gene Z, and Gene Z is to be optimized for expression in the yeast; performing a first alignment of Gene Z and the yeast gene/cDNA sequences; obtaining a protein sequence encoded by Gene Z; obtaining a protein sequence encoded by the yeast gene/cDNA; performing a second alignment of the protein sequences encoded by Gene Z and the yeast gene/cDNA; identifying positions in the first alignment where codons that mutually correspond to each other in Gene Z and yeast gene/cDNA sequences encode the same amino acid at mutually corresponding positions in the second alignment; and replacing the codon in Gene Z with the codon in the yeast gene/cDNA, if the codons in Gene Z and yeast gene/cDNA that encode the same amino acid at mutually corresponding positions in the second alignment are different between Gene Z and the yeast gene/cDNA, thereby obtaining a codon optimized Gene Z. Positions in the first alignment are identified where codons in Gene Z lack corresponding codons in the yeast gene/cDNA sequences; and replaced with codons in Gene Z lacking corresponding codons in the yeast gene/cDNA by selecting codons from the yeast that encode the same amino acid. Codon from the yeast are selected based on a frequency of usage of a codon encoding a particular amino acid in the yeast. Following codon optimization by reverse harmonization, a protein encoded by the codon optimized Gene Z is expressed more efficiently and at a higher level in the yeast as compared to a codon non-optimized Gene Z. Example 11 [0292] Reverse harmonization for codon optimization is performed by obtaining a sequence of one or more of the sequences shown in Table 2 (Gene A encoding an enzyme for ethanol production) to be optimized; obtaining a sequence of a bacterial gene/cDNA from a bacteria, wherein the bacterial gene/cDNA is an ortholog of Gene A, and Gene A is to be optimized for expression in the bacteria; performing a first alignment of Gene A and the bacteria gene/cDNA sequences; obtaining a protein sequence encoded by Gene A; obtaining a protein sequence encoded by the bacteria gene/cDNA; performing a second alignment of the protein sequences encoded by Gene A and the bacteria gene/cDNA; identifying positions in the first alignment where codons that mutually correspond to each other in Gene A and bacteria gene/cDNA sequences encode the same amino acid at mutually corresponding positions in the second alignment; and replacing the codon in Gene A with the codon in the bacteria gene/cDNA, if the codons in Gene A and bacteria gene/cDNA that encode the same amino acid at mutually corresponding positions in the second alignment are different between Gene A and the bacteria gene/cDNA, thereby obtaining a codon optimized Gene A. Positions in the first alignment are identified where codons in Gene A lack corresponding codons in the bacteria gene/cDNA sequences; and replaced with codons in Gene A lacking corresponding codons in the bacteria gene/cDNA by selecting codons from the bacteria that encode the same amino acid. Codon from the bacteria are selected based on a frequency of usage of a codon encoding a particular amino acid in the bacteria. Following codon optimization by reverse harmonization, a protein encoded by the codon optimized Gene A is expressed more efficiently and at a higher level in the bacteria as compared to a codon non- optimized Gene A. [0293] It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and indefinite articles such as "a" or "an" (e.g., “a” and/or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (e.g., the bare recitation of "two recitations," without other modifiers, means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “ a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “ a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.” [0294] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group. [0295] Any of the features of an embodiment of the first through eleventh aspects is applicable to all aspects and embodiments identified herein. Moreover, any of the features of an embodiment of the first through eleventh aspects is independently combinable, partly or wholly with other embodiments described herein in any way, e.g., one, two, or three or more embodiments may be combinable in whole or in part. Further, any of the features of an embodiment of the first through eleventh aspects may be made optional to other aspects or embodiments. References: [0296] 1. Helman, G., I. Pacheco-Colon, and A.L. Gropman, The urea cycle disorders. Semin Neurol, 2014.34(3): p.341-9. [0297] 2. Mew, N.A., et al., Urea Cycle Disorders Overview, in Gene Reviews, M.P. Adam, et al., Editors. 2003 Apr 29 [Updated 2017 Jun 22], University of Washington: Seattle, Washington. [0298] 3. McCullough, B.A., et al., Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. Am J Med Genet, 2000.93(4): p.313-9. [0299] 4. Diez-Fernandez, C., et al., Kinetic mutations in argininosuccinate synthetase deficiency: characterisation and in vitro correction by substrate supplementation. J Med Genet, 2016.53(10): p.710-9. [0300] 5. Trevisson, E., et al., Functional complementation in yeast allows molecular characterization of missense argininosuccinate lyase mutations. J Biol Chem, 2009.284(42): p.28926-34. [0301] 6. Cheng, M.Y., et al., Import and processing of human ornithine transcarbamoylase precursor by mitochondria from Saccharomyces cerevisiae. Proc Natl Acad Sci U S A, 1987.84(12): p.4063-7. [0302] 7. Gamble, C.E., et al., Adjacent Codons Act in Concert to Modulate Translation Efficiency in Yeast. Cell, 2016.166(3): p.679-690. [0303] Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in medicine : official journal of the American College of Medical Genetics 17, 405- 424.